Education
About Us
Working with TipRanks
Follow Us
2cureX AB (SE:2CUREX)
:2CUREX
2CUREX Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr0.33 - kr5.52
Previous CloseN/A
Volume2.79K
Average Volume (3M)119.69K
Market Cap
€52.21M
Enterprise Valuekr73.47M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Nov 20, 2025EPS EstimateN/A
Last Dividend Ex-Date
Jun 27, 2025Dividend Yield4.08%
Share Statistics
EPS (TTM)-0.08
Shares Outstanding25,102,917
10 Day Avg. Volume49,794
30 Day Avg. Volume119,691
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
2CUREX FAQ
What was 2cureX AB’s price range in the past 12 months?
2cureX AB lowest stock price was kr0.33 and its highest was kr5.52 in the past 12 months.
What is 2cureX AB’s market cap?
2cureX AB’s market cap is €52.21M.
When is 2cureX AB’s upcoming earnings report date?
2cureX AB’s upcoming earnings report date is Nov 20, 2025 which is in 51 days.
How were 2cureX AB’s earnings last quarter?
2cureX AB released its earnings results on Aug 21, 2025. The company reported -kr0.078 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.078.
Is 2cureX AB overvalued?
According to Wall Street analysts 2cureX AB’s price is currently Overvalued.
Does 2cureX AB pay dividends?
2cureX AB pays a Notavailable dividend of kr0.084 which represents an annual dividend yield of 4.08%. See more information on 2cureX AB dividends here
What is 2cureX AB’s EPS estimate?
2cureX AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 2cureX AB have?
2cureX AB has 25,102,917 shares outstanding.
What happened to 2cureX AB’s price movement after its last earnings report?
2cureX AB reported an EPS of -kr0.078 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 11.178%.
Which hedge fund is a major shareholder of 2cureX AB?
Currently, no hedge funds are holding shares in SE:2CUREX
Company Description
2cureX AB
2cureX AB (publ) operates as a medtech company in Europe. Its principal product is IndiTreat, an IVD test, which helps to predict cancer patient's response and resistance to different drugs and select the appropriate treatment. The company is also conducting various clinical programs for IndiTreat for breast colorectal, ovarian, and pancreatic cancers. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.
Technical Analysis
OncoZenge AB
―
LIDDS AB
―
ExpreS2ion Biotech Holding AB
―
CombiGene AB
―
Sprint Bioscience AB
―